Pregnant women's choices for preventing respiratory syncytial virus (RSV)

被引:0
|
作者
Wang, Bing [1 ,2 ,3 ]
Lassi, Zohra [4 ,5 ]
Andraweera, Prabha [1 ,2 ,3 ]
Chen, Gang [6 ]
Ong, Jason J. [7 ,8 ]
Mcmillian, Mark [1 ,2 ,3 ]
Marshall, Helen [1 ,2 ,3 ]
机构
[1] Womens & Childrens Hlth Network, Vaccinol & Immunol Res Trials Unit, 72 King William Rd, Adelaide, SA 5006, Australia
[2] Univ Adelaide, Robinson Res Inst, Adelaide, SA, Australia
[3] Univ Adelaide, Adelaide Med Sch, Adelaide, SA, Australia
[4] Univ Adelaide, Robinson Res Inst, Adelaide, Australia
[5] Univ Adelaide, Fac Hlth & Med Sci, Sch Publ Hlth, Adelaide, Australia
[6] Univ Melbourne, Sch Populat & Global Hlth, Melbourne, Vic, Australia
[7] Monash Univ, Sch Translat Med, Melbourne, Vic, Australia
[8] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, London, England
关键词
RSV; Maternal vaccine; Vaccine attitudes; Qualitative; Vaccine promotion; VACCINATION; CHALLENGES; CHILDREN;
D O I
10.1016/j.vaccine.2025.126790
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Introduction: Respiratory syncytial virus (RSV) is the leading cause of bronchiolitis and pneumonia in infants and can lead to severe respiratory distress, especially in very young infants. No specific treatments exist for RSV. However, new preventative strategies have become available including RSV vaccine for pregnant women and monoclonal antibody for infants. This study aimed to identify and understand barriers and facilitators to the uptake of a new RSV vaccine in pregnant women and determine their underlying choices for a maternal RSV immunisation program. Additionally, the study investigated choice for maternal vaccination or administration of a long-lasting monoclonal antibody to infants. Methods: Eligible participants were pregnant women residing in Australia and aged 18 years or older. Focus group discussions and individual online interviews were conducted and data were analysed using a thematic analysis approach. Results: A total of 34 pregnant women participated in online focus group discussions or interviews, with an average age of 34 years. The identified themes were categorised into four overarching domains: 1) motivators for vaccinating during pregnancy to safeguard their babies and prevent severe diseases, 2) barriers to vaccination including vaccine safety concerns, uncertainties regarding vaccine effectiveness, and vaccine hesitancy arising from COVID-19 vaccination experiences, 3) preferred vaccination promotion strategies, including constant reminders/prompts, personalised messages, campaign focusing on serious outcomes and using diverse/lay languages, recommendations from local obstetricians and health authorities, 4) clear vaccine recommendation policies and a preference for maternal immunisation over infant immunisation. Conclusions: The maternal RSV vaccination was generally welcomed and preferred by pregnant women in our study comparing to other strategies. Preferences for RSV program promotion included diversity in languages, "nudge" reminders, and recommendations from healthcare providers.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] Repurposing of antiparasitic niclosamide to inhibit respiratory syncytial virus (RSV) replication
    Niyomdecha, Nattamon
    Suptawiwat, Ornpreya
    Boonarkart, Chompunuch
    Thitithanyanont, Arunee
    Auewarakul, Prasert
    VIRUS RESEARCH, 2021, 295
  • [22] Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease
    Elaine M. Castilow
    Matthew R. Olson
    Steven M. Varga
    Immunologic Research, 2007, 39 : 225 - 239
  • [23] Current and emerging pharmacotherapy for respiratory syncytial virus (RSV) infection in infants
    Principi, Nicola
    Autore, Giovanni
    Perrone, Serafina
    Esposito, Susanna
    EXPERT OPINION ON PHARMACOTHERAPY, 2023, 24 (06) : 747 - 762
  • [24] Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease
    Castilow, Elaine M.
    Olson, Matthew R.
    Varga, Steven M.
    IMMUNOLOGIC RESEARCH, 2007, 39 (1-3) : 225 - 239
  • [25] Pregnant women's knowledge and attitude to maternal vaccination including group B streptococcus and respiratory syncytial virus vaccines
    Giles, Michelle L.
    Buttery, Jim
    Davey, Mary-Ann
    Wallace, Euan
    VACCINE, 2019, 37 (44) : 6743 - 6749
  • [26] Repurposing Probenecid to Inhibit SARS-CoV-2, Influenza Virus, and Respiratory Syncytial Virus (RSV) Replication
    Tripp, Ralph A.
    Martin, David E.
    VIRUSES-BASEL, 2022, 14 (03):
  • [27] Parental knowledge about respiratory syncytial virus (RSV) and attitudes to infant immunization with monoclonal antibodies
    Lee Mortensen, Gitte
    Harrod-Lui, Kelly
    EXPERT REVIEW OF VACCINES, 2022, 21 (10) : 1523 - 1531
  • [29] Characteristics of the First Italian Older Adults Vaccinated with an Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine
    Domnich, Alexander
    Orsi, Andrea
    Lai, Piero Luigi
    Massaro, Elvira
    Trombetta, Carlo-Simone
    Pastorino, Julieta
    Roihl, Charlott
    Pianta, Marianna
    Icardi, Giancarlo
    Panatto, Donatella
    MEDICINA-LITHUANIA, 2025, 61 (01):
  • [30] Premature Infants With Respiratory Syncytial Virus (RSV): The Need for Both Maternal and Pediatric RSV Prevention Strategies
    Nicholson, Erin G.
    Piedra, Pedro A.
    JOURNAL OF INFECTIOUS DISEASES, 2020, 222 (07) : 1070 - 1072